Search research articles
Contact Us
Filters
Showing results (681-690 of 719) with videos related to
Page
of 72
Sort By:
Clinical and Translational Radiation Oncology
|
February 12, 2026
Dynamic immune changes after bone marrow sparing VMAT in women with locally advanced cervical cancer treated with chemoradiotherapy
Anouk Corbeau, Marij J P Welters, Sanne Boekestijn, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 1, 2017
Clinical consequences of upfront pathology review in the randomised PORTEC-3 trial for high-risk endometrial cancer
S M de Boer, B G Wortman, T Bosse, et al.
Nature Communications
|
March 17, 2022
Tertiary lymphoid structures critical for prognosis in endometrial cancer patients
Nanda Horeweg, Hagma H Workel, Dominik Loiero, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc
|
January 8, 2024
Molecular and Clinicopathologic Characterization of Mismatch Repair-Deficient Endometrial Carcinoma Not Related to MLH1 Promoter Hypermethylation
Merve Kaya, Cathalijne C B Post, Carli M Tops, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology
|
August 11, 2025
Changes in bone marrow fat fraction and immune cell counts in women with cervical cancer treated with primary chemoradiotherapy
A Corbeau, E Astreinidou, S C Kuipers, et al.
Acta Oncologica (Stockholm, Sweden)
|
October 5, 2019
The relative effectiveness of eribulin for advanced breast cancer treatment: a study of the southeast Netherlands advanced breast cancer registry
X G L V Pouwels, S M E Geurts, B L T Ramaekers, et al.
Medrxiv : the Preprint Server for Health Sciences
|
September 4, 2024
Large-scale CSF proteome profiling identifies biomarkers for accurate diagnosis of Frontotemporal Dementia
Yanaika S Hok-A-Hin, Lisa Vermunt, Carel F W Peeters, et al.
Cancers
|
October 23, 2021
PROTECT: Prospective Phase-II-Trial Evaluating Adaptive Proton Therapy for Cervical Cancer to Reduce the Impact on Morbidity and the Immune System
Anouk Corbeau, Remi A Nout, Jan Willem M Mens, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 5, 2020
Molecular Classification of the PORTEC-3 Trial for High-Risk Endometrial Cancer: Impact on Prognosis and Benefit From Adjuvant Therapy
Alicia León-Castillo, Stephanie M de Boer, Melanie E Powell, et al.
British Journal of Cancer
|
October 26, 2018
Ten-year results of the PORTEC-2 trial for high-intermediate risk endometrial carcinoma: improving patient selection for adjuvant therapy
B G Wortman, C L Creutzberg, H Putter, et al.
Page
of 72
Search research articles
Search
Showing results (681-690 of 719) with videos related to
Sort By:
Page
of 72
Clinical and Translational Radiation Oncology
|
February 12, 2026
Dynamic immune changes after bone marrow sparing VMAT in women with locally advanced cervical cancer treated with chemoradiotherapy
Anouk Corbeau, Marij J P Welters, Sanne Boekestijn, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 1, 2017
Clinical consequences of upfront pathology review in the randomised PORTEC-3 trial for high-risk endometrial cancer
S M de Boer, B G Wortman, T Bosse, et al.
Nature Communications
|
March 17, 2022
Tertiary lymphoid structures critical for prognosis in endometrial cancer patients
Nanda Horeweg, Hagma H Workel, Dominik Loiero, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc
|
January 8, 2024
Molecular and Clinicopathologic Characterization of Mismatch Repair-Deficient Endometrial Carcinoma Not Related to MLH1 Promoter Hypermethylation
Merve Kaya, Cathalijne C B Post, Carli M Tops, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology
|
August 11, 2025
Changes in bone marrow fat fraction and immune cell counts in women with cervical cancer treated with primary chemoradiotherapy
A Corbeau, E Astreinidou, S C Kuipers, et al.
Acta Oncologica (Stockholm, Sweden)
|
October 5, 2019
The relative effectiveness of eribulin for advanced breast cancer treatment: a study of the southeast Netherlands advanced breast cancer registry
X G L V Pouwels, S M E Geurts, B L T Ramaekers, et al.
Medrxiv : the Preprint Server for Health Sciences
|
September 4, 2024
Large-scale CSF proteome profiling identifies biomarkers for accurate diagnosis of Frontotemporal Dementia
Yanaika S Hok-A-Hin, Lisa Vermunt, Carel F W Peeters, et al.
Cancers
|
October 23, 2021
PROTECT: Prospective Phase-II-Trial Evaluating Adaptive Proton Therapy for Cervical Cancer to Reduce the Impact on Morbidity and the Immune System
Anouk Corbeau, Remi A Nout, Jan Willem M Mens, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 5, 2020
Molecular Classification of the PORTEC-3 Trial for High-Risk Endometrial Cancer: Impact on Prognosis and Benefit From Adjuvant Therapy
Alicia León-Castillo, Stephanie M de Boer, Melanie E Powell, et al.
British Journal of Cancer
|
October 26, 2018
Ten-year results of the PORTEC-2 trial for high-intermediate risk endometrial carcinoma: improving patient selection for adjuvant therapy
B G Wortman, C L Creutzberg, H Putter, et al.
Page
of 72